ArticleJournal of neurovirology2013
Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil.
Article in Journal of neurovirology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors for HIV-associated neurocognitive impairment and frailty in aging people with HIV in Latin America: a systematic review.BMC neurology · 2026Pooled it
- Serum MMP-3/TIMP-1 ratio is a potential diagnostic marker for HIV-associated neurocognitive disorders.Research square · 2026Article
- Limited HIV-associated neuropathologies and lack of immune activation in sub-saharan African individuals with late-stage subtype C HIV-1 infection.Journal of neurovirology · 2024Article
- Sex differences in cognitive function among people with HIV-1 clade C infection in Northern India.Journal of neurovirology · 2023Article
- Cerebrospinal fluid CD14Journal of neurovirology · 2023Article
- CD3Journal of neuroimmunology · 2023Article
- Soluble CD14 is subtype-dependent in serum but not in cerebrospinal fluid in people with HIV.Journal of neuroimmunology · 2022Article
- Main lymphocyte subpopulations in cerebrospinal fluid and peripheral blood in HIV-1 subtypes C and B.Journal of neurovirology · 2022Article
- International HIV Dementia Scale for HIV-Associated Neurocognitive Disorders: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2021Review
- IgG intrathecal synthesis in HIV-associated neurocognitive disorder (HAND) according to the HIV-1 subtypes and pattern of HIV RNA in CNS and plasma compartments.Journal of neuroimmunology · 2021Article
- HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil.Journal of neurovirology · 2021Observational
- Characterization of HIV-Associated Neurocognitive Impairment in Middle-Aged and Older Persons With HIV in Lima, Peru.Frontiers in neurology · 2021Article
- Effects of HIV infection, antiretroviral therapy, and immune status on the speed of information processing and complex motor functions in adult Cameroonians.Scientific reports · 2020Article
- Neurocytoskeleton Proteins in Cerebrospinal Fluid of People With HIV-1 Subtypes B and C.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Attention/Working Memory, Learning and Memory in Adult Cameroonians: Normative Data, Effects of HIV Infection and Viral Genotype.Journal of the International Neuropsychological Society : JINS · 2020Article
- Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape.Journal of neurovirology · 2020Article
- Blood amyloid-β protein isoforms are affected by HIV-1 in a subtype-dependent pattern.Journal of neurovirology · 2020Article
- The neurologic phenotype of South African patients with HIV-associated neurocognitive impairment.Neurology. Clinical practice · 2020Article
- Cognitive Impairment in Zambians With HIV Infection and Pulmonary Tuberculosis.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Effects of HIV on executive function and verbal fluency in Cameroon.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
HIV-1 clade C isolates show reduced Tat protein chemoattractant activity compared with clade B. This might influence neuropathogenesis by altering trafficking of monocytes into the CNS. A previous study suggested low rates of HIV-associated dementia in clade C-infected individuals. The present study evaluated neurocognitive impairment rates in clade B- and C-infected individuals from the same local population. HIV+ and HIV- participants were recruited from the same geographic region in Southern Brazil. We evaluated neuropsychological (NP) impairment using a screening instrument (the International HIV Dementia Scale (IHDS)), as well as a Brazilian Portuguese adaptation of a comprehensive battery that has demonstrated sensitivity to HIV-associated neurocognitive disorders (HAND) internationally. NP performance in controls was used to generate T scores and impairment ratings by the global deficit score (GDS) method. Clade assignments were ascertained by sequencing pol and env. Blood and cerebrospinal fluid were collected from all HIV+ participants. HIV+ and HIV- participants were comparable on demographic characteristics. HIV+ participants overall were more likely to be impaired than HIV- by the IHDS and the GDS. Clade B- and C-infected individuals were demographically similar and did not differ significantly in rates of impairment. The prevalence of pleocytosis, a marker of intrathecal cellular chemotaxis, also did not differ between clade B and C infections. Clade B and C HIV-infected individuals from the same geographic region, when ascertained using comparable methods, did not differ in their rates of neurocognitive impairment, and there was no evidence of differences in CNS chemotaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.